|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Vitro Diagnostics (VODG) Release: New Results Reveal Extensive Competitive Advantages of VitroGrow(TM) Stem Cell Culture Media
12/15/2010 8:55:48 AM
GOLDEN, Colo.--(BUSINESS WIRE)--Vitro Diagnostics, Inc. (OTCBB: VODG) (OTCQB: VODG), dba Vitro Biopharma, announced completion of studies comparing its mesenchymal stem cell culture media, VitroGrow™, to major competitors showing distinct performance improvements over competing products. These new results showed that VitroGrow™ consistently improved mesenchymal stem cell growth, quality, potency and cellular recovery over leading competitors including comparable products sold by InVitrogen, Lonza and Stem Cell Technologies. Furthermore, VitroGrow™ also exhibits real-time stability that exceeds 1 year while competitors published recommended usage periods are 2 weeks to 4 weeks, thus resulting in substantial cost savings and expanded usage opportunities to VitroGrow™ customers.
|
|
|
|
|
|
|
|
|
|
|